MRM. Recasens

M. Recasens

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


M. Recasens has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Asymptomatic bilateral adrenal pheochromocytoma in a patient with a germline V804M mutation in the RET proto‐oncogene

    by M. Recasens, J. Oriola, J. M. Fernández‐Real, J. Roig, J. I. Rodríguez‐Hermosa, J. A. Font, P. Galofre, A. López‐Bermejo, W. Ricart

    Summary: A diagnosis of bilateral pheochromocytoma warrants exclusion of hereditary pheochromocytoma.Objective  To describe the first case of a bilateral pheochromocytoma associated with V804M mutation in the RET proto‐oncogene.Patients  The index case was a 54‐year‐old man with bilateral adrenal masses discovered during a CT scan performed for other reasons.Measurements  Genetic analysis included exons 8–11 and 13–17 in the RET proto‐oncogene, all four exons and flanking intronic regions in the SDHD gene, all eight exons and flanking intronic regions in the SDHB, and all three exons in the VHL gene.Results  Investigations revealed elevated urinary metanephrines (32·3 µmol/day), and laparoscopic bilateral adrenalectomy confirmed bilateral pheochromocytomas.A heterozygous V804M mutation in exon 14 of the RET was found in the index case and in four relatives. Total thyroidectomy, performed in four of five affected members in this kindred, disclosed a medullary thyroid carcinoma in the index case and in a 50‐year‐old woman, and nodular C‐cell hyperplasia in the other two subjects.Conclusions  This clinical case suggests that individuals carrying the germline V804M mutation should be screened annually for the presence of pheochromocytoma.


    • 24 September 2004
      • Vol. 48  (2) , 49-54

    [Obesity and inflammation].

    by M Recasens, W Ricart, J M Fernández-Real

    The adipose tissue produces a vast number of molecules called adipokines such as leptin, tumoral necrosis factor (TNFalpha), interleukins and adiponectin. Many of the metabolic disturbances associated with obesity and the metabolic syndrome may be due to citokine production by adipocytes. The adipose tissue increases the soluble fractions of TNFalpha leading to a rise in its biological activity. The activation of TNFalpha system causes insulin resistance through different mechanisms such as defects in receptor fosforilation and reduction in insulin-sensitive glucose transporters. TNFalpha is also involved in the pathophysiology of hypertension and dyslipidaemia associated with obesity and insulin resistance. More than one third of interleukin-6 (IL-6) concentrations come from the adipocytes. It has been demonstrated a role for IL-6 in the development of hyperlipidemia, diabetes and hypertension. In contrast to the rest of adipokines, adiponectin is reduced in obesity, diabetes or cardiovascular disease. Adiponectin improves insulin resistance, dyslipidaemia and adhesion to endothelial cells protecting from atherosclerosis development. Thus, adipokines have an important role in the pathophysiology of metabolic syndrome by different mechanisms involving metabolic and vascular effects.